Like taking painkillers while running on an injured ankle
Long after chemotherapy clears the most aggressive cancer cells, a quieter threat remains — senescent 'zombie' cells that neither grow nor die, but slowly poison their surroundings. Researchers at Imperial College London, publishing in Nature Cell Biology, have identified drugs that strip these cells of their last defense, a protein called GPX4, triggering an iron-driven self-destruction known as ferroptosis. In mouse models across three cancer types, the approach shrank tumors and extended survival, suggesting that what medicine once considered a treatment success may itself be a hidden vulnerability worth targeting.
- Chemotherapy's blind spot has been hiding in plain sight — the zombie cells it leaves behind don't divide, but they actively corrupt surrounding tissue, fuel metastasis, and distort immune responses.
- After screening 10,000 compounds, researchers zeroed in on GPX4, a protein that senescent cells overproduce like a painkiller masking a deepening wound, keeping ferroptosis — a lethal iron-triggered collapse — artificially at bay.
- Three of four lead drug candidates converged independently on the same target, a convergence that gave scientists unusual confidence they had found something real rather than coincidental.
- In every mouse model tested, blocking GPX4 and unleashing ferroptosis reduced tumor size and improved survival, suggesting the strategy could amplify the power of chemotherapy already in use.
- The critical unknowns now are whether eliminating senescent cells also awakens beneficial immune responses, and which cancer types or patient profiles stand to gain the most from this approach.
Cancer cells that stop dividing are not necessarily harmless. After chemotherapy clears the fastest-growing tumor cells, a residual population often persists — senescent cells, sometimes called zombie cells, suspended between life and death. They no longer multiply, but they quietly release molecules that damage neighboring tissue, encourage metastasis, and provoke harmful immune responses. For years, inducing senescence was considered a treatment success. Researchers now understand the picture is more complicated.
Postdoctoral researcher Mariantonietta D'Ambrosio, leading a study published in Nature Cell Biology, helped reframe the question: rather than simply stopping cancer cells from dividing, what if the senescent survivors could be eliminated entirely? To find out, her team screened 10,000 compounds against both senescent and healthy cells, focusing on covalent molecules capable of permanently disabling proteins once considered untargetable.
Three of their four most promising candidates pointed to the same protein: GPX4. This protein acts as a cellular bodyguard, shielding cells from ferroptosis — a form of death driven by iron accumulation and reactive oxygen species. Senescent cells, it turns out, survive by flooding themselves with GPX4, suppressing the dangerous internal conditions building up around them. Blocking GPX4 removes that shield, and ferroptosis follows.
Tested across three mouse cancer models, the approach consistently reduced tumor size and improved survival. Senior author Professor Jesus Gil notes that the next essential step is understanding how the immune system responds — whether clearing senescent cells also activates T cells and natural killer cells that help destroy tumors, and which patients or cancer types are most likely to benefit. The researchers, joined by collaborators in Switzerland and Germany, see senescence targeting not as a replacement for existing therapies, but as a meaningful addition to them.
Cancer cells that stop dividing can be just as dangerous as the ones that keep multiplying. After chemotherapy kills rapidly growing tumor cells, a different kind of cell often remains behind—senescent cells, sometimes called zombie cells because they linger in a state between life and death. These cells don't grow anymore, which sounds like a win. But they're quietly destructive. They release molecules that damage surrounding tissue, encourage cancer to spread to other parts of the body, and trigger the wrong kind of immune response. They're also linked to aging-related diseases like fibrosis. For years, doctors thought senescence was a good outcome. Now researchers understand it's more complicated.
Mariantonietta D'Ambrosio, a postdoctoral researcher leading a study published in Nature Cell Biology, describes the shift in thinking. Chemotherapy works by stopping cells from dividing, which is the core of what makes cancer dangerous. But over time, the senescent cells that survive begin secreting factors that push neighboring cells toward more aggressive behavior, metastasis, and immune system dysfunction. The question became: what if we could kill these cells entirely instead of just stopping them from growing?
To find an answer, the research team screened 10,000 different compounds, testing each one on both senescent and healthy cells. They worked with collaborators from Imperial's Department of Medicinal Chemistry and focused on a class of molecules called covalent compounds—drugs that can permanently attach to target proteins and block ones that were previously thought untargetable. After narrowing the field to four promising candidates, they discovered that three of them targeted the same protein: GPX4.
GPX4 acts as a bodyguard inside cells, protecting them from ferroptosis, a form of cell death triggered by high iron levels and reactive oxygen species. Recent research had shown that senescent cells are especially vulnerable to ferroptosis, which made GPX4 an attractive target. The senescent cells appear to survive by producing unusually high levels of GPX4 to counteract the dangerous conditions building up inside them—like taking painkillers while continuing to run on an injured ankle. The underlying damage persists, but the symptoms stay suppressed. By blocking GPX4 with these new drugs, researchers remove that protective shield. Without it, ferroptosis becomes inevitable, and the senescent cells die.
The team tested the approach in three different mouse models of cancer. In all three, killing senescent cells reduced tumor size and increased survival. The results suggest the strategy could work alongside existing chemotherapy and immunotherapy, targeting a part of cancer biology that has largely been overlooked. But questions remain. Professor Jesus Gil, head of the Senescence group at the research institution and senior author of the study, points out that the next critical step is understanding how the treatment affects the immune system. Does eliminating senescent cells also activate the beneficial parts of immunity—T cells and natural killer cells that help destroy tumors? And which cancer types or which patients would benefit most? If a patient undergoing chemotherapy has tumors that overproduce GPX4, this approach might amplify the effectiveness of existing drugs.
The researchers believe senescence targeting represents a significant opportunity for cancer treatment, one that could serve as a supporting role alongside chemotherapy and immunotherapy. Scientists from the Institute of Oncology Research in Switzerland and the M3 Research Centre at the University of Tübingen in Germany also contributed to the work. The path forward involves moving from mouse models to human trials, understanding the immune dynamics, and identifying which patients are most likely to respond.
Notable Quotes
Senescent cells secrete factors that influence neighboring cells and induce more proliferation, metastasis, and recruitment of harmful immune system activity that provokes tumor aggressiveness.— Mariantonietta D'Ambrosio, postdoctoral researcher and lead author
Targeting senescence is a huge opportunity for cancer treatments and can play a supporting role in addition to chemotherapy and immunotherapy.— Mariantonietta D'Ambrosio
The Hearth Conversation Another angle on the story
So these zombie cells—they're not growing, but they're still causing trouble. How does that work?
They're metabolically active even though they've stopped dividing. They're constantly secreting molecules that damage nearby tissue and encourage other cancer cells to spread. It's like having a saboteur in the room who isn't moving but is actively making things worse.
And chemotherapy actually creates more of them?
Yes. Chemotherapy is designed to stop cells from dividing, which is good at shrinking tumors in the short term. But it leaves behind these senescent cells that survive the treatment. Over time, their harmful effects can outweigh the initial benefit.
This GPX4 protein—why is it so important to these cells?
It's their survival mechanism. These cells are sitting on the edge of a kind of iron-triggered collapse. GPX4 protects them from that. Without it, they can't survive. The new drugs essentially remove the painkiller while the ankle is still injured.
And in the mouse studies, what happened when you blocked GPX4?
The senescent cells died, tumors shrank, and the mice survived longer. But we still need to understand whether killing these cells also wakes up the immune system in helpful ways—whether it recruits the cells that actually fight cancer.
So this isn't a replacement for chemotherapy?
Not yet. It looks like it could be a companion to it. You give chemotherapy, it creates senescent cells, then you use this new drug to eliminate them. Together, they might work better than either alone.